Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on rare disease treatments, has announced a proposed underwritten public offering of common stock shares. The company plans to grant underwriters a 30-day option to purchase additional shares equal to 15% of those sold in the offering. Piper Sandler and Oppenheimer & Co. are acting as joint book-running managers. Capricor intends to use the net proceeds for product candidate development, manufacturing, working capital, and general corporate purposes. The offering is made pursuant to an effective shelf registration statement and will be conducted via a prospectus and related supplement. The final terms are subject to market conditions, with no assurance of completion.
Capricor Therapeutics (NASDAQ: CAPR), un'azienda biotecnologica focalizzata sul trattamento delle malattie rare, ha annunciato un offerta pubblica sottoscritta proposta di azioni ordinarie. L'azienda prevede di concedere agli underwriter un'opzione di 30 giorni per acquistare ulteriori azioni pari al 15% di quelle vendute nell'offerta. Piper Sandler e Oppenheimer & Co. stanno operando come manager congiunti di book-running. Capricor intende utilizzare i proventi netti per lo . L'offerta è realizzata ai sensi di una registrazione a scaffale efficace e sarà condotta tramite un prospetto e un supplemento correlato. I termini finali sono soggetti a condizioni di mercato, senza alcuna certezza di completamento.
Capricor Therapeutics (NASDAQ: CAPR), una empresa biotecnológica centrada en tratamientos para enfermedades raras, ha anunciado una oferta pública de acciones suscrita propuesta. La compañía planea otorgar a los suscriptores una opción de 30 días para comprar acciones adicionales equivalentes al 15% de las vendidas en la oferta. Piper Sandler y Oppenheimer & Co. están actuando como gerentes conjuntos de book-running. Capricor tiene la intención de utilizar los ingresos netos para el desarrollo de candidatos de producto, fabricación, capital de trabajo y propósitos corporativos generales. La oferta se realiza de acuerdo con una declaración de registro en estante efectiva y se llevará a cabo a través de un prospecto y un suplemento relacionado. Los términos finales están sujetos a las condiciones del mercado, sin ninguna garantía de finalización.
Capricor Therapeutics (NASDAQ: CAPR)는 희귀 질병 치료에 주력하는 생명공학 회사로, 제안된 인수 공개 제안을 발표했습니다. 이 회사는 언더라이터에게 판매된 주식의 15%에 해당하는 추가 주식 구매를 위한 30일 옵션을 부여할 계획입니다. Piper Sandler와 Oppenheimer & Co.가 공동 서적 관리자로 활동하고 있습니다. Capricor는 제품 후보 개발, 제조, 운전 자본 및 일반 기업 목적을 위한 순익을 사용할 예정입니다. 이 제안은 유효한 선반 등록 성명서에 따라 이루어지며, 설명서 및 관련 보충서를 통해 진행됩니다. 최종 조건은 시장 상황에 따라 달라지며, 완료에 대한 보장은 없습니다.
Capricor Therapeutics (NASDAQ: CAPR), une entreprise biotechnologique axée sur les traitements des maladies rares, a annoncé une offre publique proposée sous écriture d'actions ordinaires. L'entreprise prévoit d'accorder aux souscripteurs une option de 30 jours pour acheter des actions supplémentaires équivalentes à 15 % de celles vendues dans le cadre de l'offre. Piper Sandler et Oppenheimer & Co. agissent en tant que gestionnaires communs. Capricor a l'intention d'utiliser le produit net pour le développement de candidats produits, la fabrication, le fonds de roulement et les objectifs d'entreprise généraux. L'offre est réalisée conformément à une déclaration d'enregistrement de nature effective et sera réalisée par le biais d'un prospectus et d'un supplément connexe. Les conditions finales sont soumises aux conditions du marché, sans aucune garantie d'achèvement.
Capricor Therapeutics (NASDAQ: CAPR), ein biotechnologisches Unternehmen, das sich auf die Behandlung seltener Krankheiten konzentriert, hat ein vorgeschlagenes, unter Anschaffung angebotenes Aktienangebot angekündigt. Das Unternehmen plant, den Underwritern eine 30-tägige Option für den Erwerb zusätzlicher Aktien in Höhe von 15 % der im Angebot verkauften Aktien einzuräumen. Piper Sandler und Oppenheimer & Co. fungieren als gemeinschaftliche Buchführung. Capricor beabsichtigt, die Nettomittel für Produktkandidatenentwicklung, Herstellung, Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Das Angebot erfolgt auf Grundlage einer wirksamen Regalgrundsatzregelung und wird über einen Prospekt und einen verwandten Nachtrag durchgeführt. Die endgültigen Bedingungen unterliegen den Marktbedingungen, ohne Garantie für den Abschluss.
- Potential to raise significant capital for product development and operations
- Effective shelf registration statement already in place, streamlining the offering process
- Reputable underwriters (Piper Sandler and Oppenheimer & Co.) managing the offering
- Potential dilution of existing shareholders' stock value
- Uncertainty regarding the offering's completion and final terms
- Market reaction to the offering may negatively impact stock price in the short term
Insights
Capricor Therapeutics' announcement of a proposed public offering of common stock is a significant development with potential implications for investors. This move suggests the company is seeking to raise additional capital, likely to fund its ongoing research and development efforts in cell and exosome-based therapeutics for rare diseases.
Key points to consider:
- The offering's size and pricing are not yet disclosed, which creates uncertainty about the extent of potential dilution for existing shareholders.
- The inclusion of a 30-day option for underwriters to purchase additional shares (up to 15% of the offering) could further impact share price and ownership structure.
- The involvement of reputable underwriters like Piper Sandler and Oppenheimer & Co. lends credibility to the offering.
- The company plans to use the proceeds for product development, manufacturing and working capital, which could accelerate its progress in the competitive biotech landscape.
While raising capital can provide necessary funds for growth, it often leads to short-term stock price pressure. Long-term investors should weigh the potential for accelerated development against the dilutive effects of the offering. The market's reaction to the final terms of the offering, when announced, will be important to watch.
This public offering announcement from Capricor Therapeutics highlights the capital-intensive nature of biotechnology research, especially in the field of rare diseases. The company's focus on cell and exosome-based therapeutics positions it in a cutting-edge area of medical research with significant potential but also high development costs.
Key considerations for investors:
- The timing of this offering, coming shortly after their shelf registration became effective, suggests a strategic move to capitalize on current market conditions or to meet specific funding milestones.
- The broad intended use of proceeds ("continued development of product candidates, manufacturing, working capital") indicates that Capricor is likely at a critical juncture in its development pipeline, possibly preparing for advanced clinical trials or scaling up manufacturing capabilities.
- The company's ability to secure joint book-running managers of Piper Sandler and Oppenheimer's caliber may reflect positively on the perceived potential of their therapeutic pipeline.
While this offering may provide Capricor with necessary capital to advance its programs, it's important for investors to closely examine the company's clinical progress and pipeline potential to assess the long-term value proposition against the short-term dilutive effects of the offering.
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to
Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the public offering.
The Company intends to use the net proceeds from this offering on the continued development of its product candidates, manufacturing of its product candidates, working capital and general corporate purposes.
The securities are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-280229) that was originally filed with the Securities and Exchange Commission (“SEC”) on June 14, 2024 and declared effective on October 16, 2024. The offering is being made only by means of a prospectus and related prospectus supplement. A preliminary prospectus supplement relating to the offering was filed with the SEC on October 16, 2024. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from Piper Sandler & Co. at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus and Oppenheimer & Co. Inc. at Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on August 8, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
What is the purpose of Capricor Therapeutics' (CAPR) proposed public offering?
Who are the underwriters for Capricor Therapeutics' (CAPR) proposed public offering?
What option is Capricor Therapeutics (CAPR) granting to the underwriters in the proposed offering?
When was Capricor Therapeutics' (CAPR) shelf registration statement declared effective?
